Overview
- HHS posted an interim policy that says it will not seek enforcement action for state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 when they follow specific safety conditions.
- The policy, which was posted Wednesday, allows compounding now while the FDA pursues formal rulemaking and opens a short public comment period on the interim approach.
- HHS requires that compounders use peptide ingredients from FDA-registered manufacturers with certificates of analysis, verify identity and purity, limit approved dosage forms, require patient-specific prescriptions and report serious adverse events and product-quality problems to MedWatch and states.
- Career FDA scientists largely opposed the move and warned there is insufficient evidence that the six peptides are safe or effective, while an FDA advisory panel in July narrowly recommended easing restrictions after hearings that included appointees with ties to the peptide field.
- Public-health groups and former FDA officials say the policy risks exposing patients to unproven or contaminated products, analysts and telehealth firms say it opens a multibillion-dollar market, and the decision revives long-standing concerns about compounding safety going back to the 2012 fungal meningitis outbreak and the FDA's 2023 guidance that flagged many peptides as unsafe to compound.